

Supplemental Table 1. Baseline characteristics of subjects

Subject	Age (yrs)	BMI (kg/m ²)	Body Fat (%) ^{&}	Waist Circ. (cm)	Waist-Hip-Ratio	HOMA-IR	CD4 (cells/uL)	ART Regimen
1	52	29.0	32.2	104.5	1.03	8.58	826	nvp, 3tc, tdf
2	40	28.3	38.4	107.1	1.04	9.58	440	atz, rtv, azt, 3tc, abc
3	65	24.8	21.4	100.5	1.08	3.28	700	efv, 3tc, abc
4	34	29.3	30.8	107.2	1.08	4.35	459	nfv, d4t, ddI
5	69	24.0	25.0	106.8	1.17	6.93	427	nvp, azt, 3tc, abc, tdf
6* [#]	57	28.8	31.2	109.3	1.13	9.70	827	atz, rtv, tdf, ftc
7	49	26.1	30.5	105.1	1.10	4.84	295	atz, rtv, azt, 3tc, tdf, ddi
8*	58	24.8	16.0	112.1	1.16	3.77	189	lop/r, sqv, azt, 3tc, tdf, T20
9 [#]	61	30.0	28.9	108.2	1.10	3.73	565	atz, 3tc, abc
10* [#]	50	29.6	26.3	114.4	1.14	5.00	324	nvp, 3tc, abc, tdf
11* [#]	55	29.2	34.4	117.7	1.19	5.66	414	lpv/r, 3tc, tdf
12 [#]	52	25.1	25.4	110.5	1.11	2.85	499	efv, azt, 3tc
13	48	30.6	39.1	112.3	0.99	8.21	378	ftc, tdf, efv

3tc, lamivudine; abc, abacavir; atz, atazanavir; azt, zidovudine; d4t, stavudine; ddi, didanosine; efv, efavirenz; ftc, emtricitabine; lop/r, lopinavir/ritonavir; nfv, nelfinavir; nvp, nevirapine; rtv, ritonavir; sqv, saquinavir; tdf, tenofovir; T20, enfuvirtide

* Subjects on testosterone replacement

[#] Subjects on lipid lowering medications

[&]Percent total body fat determined by DEXA